TTY Biopharm
- Company typePublic
- Founded1960
- HeadquartersTaipei, Taiwan
- Headcount—
- GTM typeB2B
- OfferingHardware or Manufacturing
TTY Biopharm firmographics
Firmographics- Name
- TTY Biopharm
- Legal name
- TTY Biopharm Company Limited
- Website
- https://eng.tty.com.tw
- Company type
- Public
- Founded year
- 1960
- Operating status
- Operating
- Ownership category
- akta.pro rank
TTY Biopharm industry classification
Industry- Product category
- Specialty Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Oncology Specialty Pharmaceuticals (HLAIACAA)
- akta.pro secondary industries
- Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI), Generic Hospital & Institutional Products (HLAIABAL)
Keywords
Where TTY Biopharm is headquartered
LocationHeadquarters
- HQ city
- Taipei
- HQ country
- Taiwan
- HQ region
- Asia
Offices5 records
Markets served
TTY Biopharm business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Operations, Supply Chain, Personnel, Technology or R&D, Marketing or Sales
Revenue model
- Pharmaceutical Product Sales: TTY generates revenue primarily through the sale of branded generic pharmaceuticals in Taiwan and international markets, including oncology drugs (TOT), anti-infective products (TIT), and healthcare products (KAM).
- CDMO/Contract Manufacturing Services: TTY offers Contract Development and Manufacturing services leveraging its PIC/S GMP certified facilities for clinical supply and commercial production.
- Licensing and Royalty Revenue: TTY receives licensing revenue including upfront payments, regulatory milestones, and supply of drug product at percentage of net selling price from partners such as PAION for remimazolam.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels1 record
TTY Biopharm product offering
Product offeringCore offering
TTY Biopharm develops, manufactures, and sells branded generic pharmaceutical products across three therapeutic divisions: Oncology (TOT), Anti-Infection (TIT), and Healthcare (KAM), sold primarily to hospitals and medical centers in Taiwan and select Asian markets. The company applies proprietary liposome and microsphere drug delivery technologies, supported by PIC/S GMP certified manufacturing facilities, and supplements its own portfolio with CDMO services and international licensing partnerships.
Differentiator
Problem solved
Functional benefit
Products and services
- TS-1 Capsule Oral anti-cancer drug (tegafur/gimeracil/oteracil combination) licensed from Taiho Pharmaceutical for development and marketing in Taiwan; used to treat gastric cancer, colorectal cancer, NSCLC, pancreatic cancer, biliary tract cancer, and metastatic breast cancer, available through hospital oncology departments.
- Yondelis (trabectedin) Marine-derived anticancer drug (trabectedin) licensed from PharmaMar for distribution in Taiwan, Hong Kong, and Macao; approved for soft tissue sarcoma in Taiwan and recurrent ovarian cancer in Hong Kong, supplied to hospital oncology units.
- Remimazolam Ultra-short-acting intravenous benzodiazepine sedative licensed from PAION AG for development and commercialization in Taiwan; used for procedural sedation during invasive medical procedures such as colonoscopy and bronchoscopy, marketed to hospitals and procedural settings.
- Broad-spectrum antibacterial (Everest Medicines) Broad-spectrum antibacterial for treatment of complicated intra-abdominal infections including MDRO/Superbug infections, licensed from Everest Medicines for exclusive commercialization in Taiwan; intended for hospital infectious disease and ICU use.
- Brosym Anti-infective injection product within TTY's Anti-Infection (TIT) division, marketed to hospitals for antibiotic therapy.
- Lipo-AB Liposomal anti-infective product within TTY's Anti-Infection (TIT) division leveraging TTY's proprietary liposome drug delivery platform; supplied to hospital infectious disease and intensive care teams.
- CDMO / Contract Development and Manufacturing Services Contract Development and Manufacturing services leveraging TTY's PIC/S GMP certified facilities and specialized liposome/microsphere technologies for clinical supply and commercial production of cytotoxic and non-cytotoxic pharmaceutical products; sold to pharmaceutical companies.
- PIC/S GMP Business Service GMP-certified manufacturing service for cytotoxic and non-cytotoxic pharmaceutical products offered through TTY's PIC/S GMP compliant facilities (Chungli, Lioudu, Neihu factories); sold to pharmaceutical partners needing certified production capacity.
- Licensing services Licensing arrangement enabling international pharmaceutical partners (e.g., PAION, PharmaMar, Taiho, Everest Medicines) to develop, manufacture, and commercialize drugs via TTY for Taiwan and other covered territories, generating upfront payments, milestones, royalties, and supply revenue.
Quantifiable outcome
- Top 1% of largest biopharmaceutical companies in Taiwan in oncology and critical infection fields
- +2 more outcomes
Companies that use TTY Biopharm
Customer profileNamed customers5 records
Segments4 records
Ideal customer profiles3 records
TTY Biopharm technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
TTY Biopharm partnerships and signals
Strategic signalScale indicators8 records
Recent moves6 records
Expansion highlights5 records
TTY Biopharm competitors and assessment
Company assessmentDirect peers
- Taiho Pharmaceutical: Taiho is the originator and licensor of TS-1 to TTY and is a Japan-based specialty oncology pharmaceutical company with comparable focus on oral cytotoxic and supportive oncology agents. Comparable along therapeutic area (oncology), portfolio composition (oral cytotoxics, antibody-derived agents), and CDMO-era specialization.
- Yung Shin Pharmaceutical Industrial: One of Taiwan's largest domestic pharmaceutical manufacturers with branded generics, injectables, and contract manufacturing. Directly comparable along geography (Taiwan), therapeutic breadth (oncology, anti-infectives, healthcare), and GMP manufacturing footprint.
- Standard Chemical & Pharmaceutical: Taiwan-listed specialty pharmaceutical company with branded generics, complex formulations, and hospital-channel distribution. Comparable along Taiwan-domestic branded generics, hospital-focused GTM, and specialty injectables.
- Center Laboratories: Taiwan-based pharmaceutical manufacturer with branded injectables, sterile manufacturing, and PIC/S GMP capability. Comparable along Taiwan footprint, sterile injectable manufacturing, and branded product orientation.
- PharmaEssentia Corporation: Taiwan-listed specialty biopharmaceutical company focused on oncology and hematology with proprietary technology platform. Comparable along Taiwan base, oncology specialty focus, and platform-driven branded specialty pipeline.
Emerging players
- PharmaMar: Spanish biopharmaceutical company focused on marine-derived oncology (Yondelis, Zepzelca). Comparable as TTY's Yondelis licensor and similarly positioned as a mid-sized specialty oncology company with marine-derived and innovative cytotoxic assets.
- OBI Pharma: Taiwan-listed clinical-stage oncology biopharmaceutical company developing novel ADCs and cancer therapeutics. Comparable along Taiwan base and oncology focus, though OBI is more R&D-stage whereas TTY has commercialized specialty oncology revenue.
Broad incumbents
- Yuhan Corporation: Korean diversified pharmaceutical company with branded specialty, generics, CDMO partnerships, and established Asia-Pacific distribution. Comparable along Asian specialty pharma scale, branded generics model, and CDMO/in-licensing strategy across oncology and anti-infectives.
- Daiichi Sankyo: Japan-headquartered global pharmaceutical leader with major oncology franchise including cytotoxic and ADC platforms. Comparable along oncology specialty focus, Asia-Pacific branded specialty distribution, and liposomal/injectable technology overlap.
- AstraZeneca Asia-Pacific: Global pharmaceutical major with extensive oncology, anti-infection, and specialty portfolio across Asia-Pacific. Comparable as the incumbent competitive set for hospital-channel oncology and anti-infective business in Taiwan and Southeast Asia where TTY operates.
Market position
Strengths5 records
Weaknesses4 records
Competitive moat4 records
Key risks4 records
Key highlights6 records
Customer concentration
TTY Biopharm social profiles
Digital presenceTTY Biopharm financial estimates
Financial estimateRevenue estimate
Valuation estimate
TTY Biopharm leadership team
Management profileNumber of profiles
Profiles5 records
TTY Biopharm subsidiaries and ownership
Company hierarchySubsidiaries3 records
TTY Biopharm funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
TTY Biopharm M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about TTY Biopharm
What does TTY Biopharm do?
TTY Biopharm develops, manufactures, and sells branded generic pharmaceutical products across three therapeutic divisions: Oncology (TOT), Anti-Infection (TIT), and Healthcare (KAM), sold primarily to hospitals and medical centers in Taiwan and select Asian markets. The company applies proprietary liposome and microsphere drug delivery technologies, supported by PIC/S GMP certified manufacturing facilities, and supplements its own portfolio with CDMO services and international licensing partnerships.
Is TTY Biopharm a public or private company?
TTY Biopharm is a public company. It is classified as public and is currently operating.
When was TTY Biopharm founded?
TTY Biopharm was founded in 1960.
Where is TTY Biopharm based?
TTY Biopharm is headquartered in Taipei, Taiwan, in the Asia region.
How does TTY Biopharm make money?
Three revenue lines are on record. Pharmaceutical Product Sales are the primary driver. The others are CDMO/Contract Manufacturing Services and licensing and Royalty Revenue.
Who are TTY Biopharm's main competitors?
Direct peers on record are Taiho Pharmaceutical, Yung Shin Pharmaceutical Industrial, Standard Chemical & Pharmaceutical, Center Laboratories and PharmaEssentia Corporation. Emerging players are PharmaMar and OBI Pharma. Broad incumbents are Yuhan Corporation, Daiichi Sankyo and AstraZeneca Asia-Pacific.
Does TTY Biopharm have an API?
No public API is recorded for TTY Biopharm.
What industry is TTY Biopharm in?
TTY Biopharm's product category is Specialty Pharmaceuticals. Its primary akta.pro industry code is HLAIACAA, Oncology Specialty Pharmaceuticals, with a secondary code of HLAIABAI, Contract Development & Manufacturing for Generics (CDMO/CMO). Its NAICS code is 325412 and its SIC code is 2834.